It is increasingly understood that multiple sclerosis (MS) relapse and progression can occur simultaneously, regardless of phenotype, revealing flaws in the traditional classification of MS and prompting increasing use of a spectrum-based view of the disease. This shift is reflected …
Endometriosis is a chronic inflammatory condition that remains underrecognized and undertreated, leaving many individuals of reproductive age with daily pain and disruption. Patients often face preference‑sensitive decisions about pain management, contraception, and fertility without clear guidance, frequently after years‑long diagnostic …
Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive, interconnected continuum in which type 2 diabetes, chronic kidney disease, heart failure, and overlapping cardiometabolic risk factors mutually accelerate one another’s progression. In everyday family medicine practice, however, these conditions are often managed in …
Despite national recommendations, PrEP remains underutilized in many clinical settings because clinicians often lack confidence, time, and practical workflows to consistently identify candidates and act on eligibility findings. Routine care frequently omits a structured sexual health history and assessment, leading …
Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive, interconnected continuum in which type 2 diabetes, chronic kidney disease, heart failure, and overlapping cardiometabolic risk factors mutually accelerate one another’s progression. In everyday family medicine practice, however, these conditions are often managed in …
Despite advances in the prevention and management of atherosclerotic cardiovascular disease (ASCVD), gaps remain in real-world risk assessment and lipid-lowering treatment, particularly among intermediate- and high-risk patients. Inconsistent use of risk assessment tools, variable evaluation of risk-enhancing factors, and suboptimal …
Alzheimer’s disease (AD) is an escalating public health challenge, with rising prevalence and profound burdens on patients, caregivers, and healthcare systems. Recent approvals of amyloid-targeting therapies (ATTs) represent a major advancement in disease-modifying treatment for early symptomatic AD. However, translating …
Alzheimer’s disease (AD) continues to impose a growing public health burden as prevalence rises alongside an aging population. Despite advancements in diagnostic tools and the emergence of Alzheimer’s-targeted therapies (ATTs), many healthcare professionals (HCPs) face challenges in integrating new evidence …
